1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study

BACKGROUND: Numerous microbiota-based therapies are being evaluated for prevention of C. difficile infection (rCDI), a public health threat with high recurrence rates associated with the current standard of care. RBX2660, a standardized microbiota-based drug, was efficacious for preventing rCDI in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mische, Sarah, Orenstein, Robert, Dubberke, Erik R, Khanna, Sahil, Hecht, Gail, Dupont, Herbert, Lee, Christine, Blount, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252947/
http://dx.doi.org/10.1093/ofid/ofy210.1606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252947/
http://dx.doi.org/10.1093/ofid/ofy210.1606

Ejemplares similares